COMP <GO>
SUPN vs HCM // 10Y YIELD & FRED MACRO BETA
Supernus Pharmaceuticals Inc. (NASDAQ) VS. HUTCHMED (China) Limited (NASDAQ) • 15-METRIC TALLY: SUPN 6
— HCM 4
■ METRIC PARITY
LAST: $41.84 (+1.85%) • MKT CAP: $2.43B
macro-sensitivity
0.88
LAST: $13.59 (+2.03%) • MKT CAP: $2.37B
macro-sensitivity
—
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (SUPN VS. HCM)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | SUPN | HCM | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | 89.60% | — | — | TIE | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | -4.50% | -2.50% | -2.00 | HCM | /roic <GO> |
| EV/EBITDA & P/E Valuation | — | — | — | TIE | /valuation <GO> |
| Free Cash Flow Yield | 1.89% | -3.32% | +5.21 | SUPN | /fcf-yield <GO> |
| Operating Margin | -8.70% | -7.10% | -1.60 | HCM | /operating-margins <GO> |
| Net Profit Margin | -5.40% | 68.00% | -73.40 | HCM | /net-margins <GO> |
| Revenue Growth (YoY) | 8.60% | -13.00% | +21.60 | SUPN | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 0.00% | 0.00% | 0.00 | TIE | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | 4.84 | 3.63 | +1.21 | SUPN | /balance-sheet <GO> |
| Piotroski F-Score Quality | 7/9 | 4/9 | +3.00 | SUPN | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | — | — | — | TIE | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 50.5 | 41.1 | +9.43 | SUPN | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta ACTIVE | 0.88 | — | — | TIE | /macro-sensitivity <GO> |
| Forward P/E Multiple | 22.0x | 4.8x | +17.20 | HCM | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $2.43B | $2.37B | $61.0M | SUPN | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | SUPN REV | HCM REV | SUPN GROSS % | HCM GROSS % | SUPN FCF | HCM FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $719.0M | $548.5M | 89.6% | 38.7% | $46.0M | -$78.8M |
| FY 2024 | $661.8M | $630.2M | 88.2% | 44.6% | $171.2M | -$17.4M |
| FY 2023 | $607.5M | $838.0M | — | — | $83.7M | $219.3M |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
SUPN // BETA 0.88
HCM // BETA —